Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBOT for Opioid Use Disorder
NCT04850664Phase 2Unknown
- Sponsor
- Evon Medics
- Start
- Mar 2021
- Primary completion
- Nov 2022
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) (2 arms), sponsored by Evon Medics. Primary endpoints: Buprenorphine Maintenance Treatment Retention at 36 weeks, Change in Subjective Opiate Withdrawal Scale at Week 24 and 2 more. Status: unknown.
02
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04850664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850664.